María Soengas: Difference between revisions
Content deleted Content added
FeanorStar7 (talk | contribs) →References: add sort tag; layout |
c/e |
||
| Line 2: | Line 2: | ||
{{Orphan|date=July 2022}} |
{{Orphan|date=July 2022}} |
||
{{Infobox scientist |
{{Infobox scientist |
||
| name = |
| name = Marisol S. Soengas |
||
| birth_date = {{Birth year and age|1968}} |
| birth_date = {{Birth year and age|1968}} |
||
| birth_place = [[Agolada]] |
| birth_place = [[Agolada]] |
||
| Line 9: | Line 9: | ||
}} |
}} |
||
''' |
'''Marisol S. Soengas''' (born 1968) is a Spanish immunologist who is a professor at the [[Spanish National Cancer Research Centre|Spanish National Cancer Research Center]] (CNIO). Her research considers melanoma and the development of new therapeutic strategies. She was elected to the [[European Molecular Biology Organization]] in 2022. |
||
== Early life and education == |
== Early life and education == |
||
Soengas was born in [[Agolada]].<ref>{{Cite web |last=www.axel-k.com |title=María S. Soengas |url=https://www.cnio.es/en/personas/maria-s-soengas-2/ |access-date=2022-07-09 |website=CNIO |language=en-US}}</ref> She was an undergraduate student at the [[University of A Coruña]], and moved to the [[Autonomous University of Madrid]] for |
Soengas was born in [[Agolada]].<ref>{{Cite web |last=www.axel-k.com |title=María S. Soengas |url=https://www.cnio.es/en/personas/maria-s-soengas-2/ |access-date=2022-07-09 |website=CNIO |language=en-US}}</ref> She was an undergraduate student at the [[University of A Coruña]], and moved to the [[Autonomous University of Madrid]] for doctoral research. She worked in [[molecular biology]] with M. Salas in the Centro de Biología Molecular Severo Ochoa. She worked as a postdoctoral scholar at the [[Cold Spring Harbor Laboratory]] and at the [[University of Michigan]].<ref name=":0">{{Cite web |date=2015-03-24 |title=Conference: ""Three-in-One" antimelanoma agents validated in vivo: differential targeting of tumor cells, the surrounding vasculature and the immune system"-Dra. Marisol Soengas, Head Melanoma Group, Dean for Academic Affairs, CNIO |url=https://www.usc.es/cimus/es/events/conference-three-one-antimelanoma-agents-validated-vivo-differential-targeting-tumor-cells |access-date=2022-07-09 |website=CiMUS - USC - Universidad de Santiago de Compostela |language=es}}</ref> At the Cold Spring Harbor Laboratory, she characterised the apoptotic factors as [[melanoma]] suppressors.<ref name=":1">{{Cite web |title=The Pezcoller-Marina Larcher Fogazzaro-EACR Women in Cancer Research Award {{!}} The European Association for Cancer Research |url=https://www.eacr.org/pezcoller-foundation-awards/women-in-cancer-research-award |access-date=2022-07-09 |website=www.eacr.org}}</ref> After deciding to expand beyond cellular/animal models, Soengas moved to the dermatology department in Michigan, home to the Multidisciplinary Melanoma Clinics.<ref name=":1" /> |
||
== Research and career == |
== Research and career == |
||
In 2008 Soengas joined the [[Spanish National Cancer Research Centre|Spanish National Cancer Research Center]] (CNIO), where she established a research |
In 2008, Soengas joined the [[Spanish National Cancer Research Centre|Spanish National Cancer Research Center]] (CNIO), where she established a research program that looked to understand [[melanoma]], and to translate cutting-edge scientific research into clinical practice.<ref name=":0" /><ref>{{Cite web |last=www.axel-k.com |title=Melanoma Group |url=https://www.cnio.es/en/research-innovation/scientific-programmes/molecular-oncology-programme/melanoma-group/ |access-date=2022-07-09 |website=CNIO |language=en-US}}</ref> Sonegas looks to identify new biomarkers of disease, and the mechanisms of cellular stress that are deregulated in melanoma. Her group were the first to describe a lymphoreporter (MetAlert) mice for non-invasive imaging of pre-metastatic niches in melanoma. This allowed her to understand the mechanisms of immune resistance as well as to generate nanoparticle-based treatments.{{cn}} |
||
Her group were the first to describe a lymphoreporter (MetAlert) mice for non-invasive imaging of pre-metastatic niches in melanoma. This allowed her to undestand the mechanisms of immune resistance as well as to generate nanoparticle-based treatments. |
|||
| ⚫ | |||
| ⚫ | |||
* Dana Ashby Young Investigator Award of the Society for Melanoma Research<ref name=":1" /> |
* Dana Ashby Young Investigator Award of the Society for Melanoma Research<ref name=":1" /> |
||
* 2009 Premio M. Josefa Wonenburger from the Xunta de Galicia<ref>{{Cite web |title=Premio María Josefa Wonenburger {{!}} Unidade Muller e Ciencia |url=https://unidadedamullereciencia.xunta.gal/es/premio-maria-josefa-wonenburger |access-date=2022-07-09 |website=unidadedamullereciencia.xunta.gal}}</ref> |
* 2009 Premio M. Josefa Wonenburger from the Xunta de Galicia<ref>{{Cite web |title=Premio María Josefa Wonenburger {{!}} Unidade Muller e Ciencia |url=https://unidadedamullereciencia.xunta.gal/es/premio-maria-josefa-wonenburger |access-date=2022-07-09 |website=unidadedamullereciencia.xunta.gal}}</ref> |
||
| Line 28: | Line 25: | ||
* 2022 Pezcoller-Marina Larcher Fogazzaro-EACR Women in Cancer Research Award<ref name=":1" /> |
* 2022 Pezcoller-Marina Larcher Fogazzaro-EACR Women in Cancer Research Award<ref name=":1" /> |
||
== |
== Selected publications == |
||
* {{Cite Q|Q31984891}} |
* {{Cite Q|Q31984891}} |
||
* {{Cite Q|Q29619550}} |
* {{Cite Q|Q29619550}} |
||
| Line 39: | Line 35: | ||
{{Authority control}} |
{{Authority control}} |
||
| ⚫ | |||
| ⚫ | |||
[[Category:Living people]] |
|||
[[Category:1968 births]] |
[[Category:1968 births]] |
||
[[Category:Autonomous University of Madrid alumni]] |
[[Category:Autonomous University of Madrid alumni]] |
||
Revision as of 13:08, 15 July 2022
Marisol S. Soengas | |
|---|---|
| Born | 1968 (age 55–56) |
| Alma mater | Autonomous University of Madrid University of A Coruña |
| Scientific career | |
| Institutions | University of Michigan Cold Spring Harbor Laboratory Spanish National Cancer Research Centre |
Marisol S. Soengas (born 1968) is a Spanish immunologist who is a professor at the Spanish National Cancer Research Center (CNIO). Her research considers melanoma and the development of new therapeutic strategies. She was elected to the European Molecular Biology Organization in 2022.
Early life and education
Soengas was born in Agolada.[1] She was an undergraduate student at the University of A Coruña, and moved to the Autonomous University of Madrid for doctoral research. She worked in molecular biology with M. Salas in the Centro de Biología Molecular Severo Ochoa. She worked as a postdoctoral scholar at the Cold Spring Harbor Laboratory and at the University of Michigan.[2] At the Cold Spring Harbor Laboratory, she characterised the apoptotic factors as melanoma suppressors.[3] After deciding to expand beyond cellular/animal models, Soengas moved to the dermatology department in Michigan, home to the Multidisciplinary Melanoma Clinics.[3]
Research and career
In 2008, Soengas joined the Spanish National Cancer Research Center (CNIO), where she established a research program that looked to understand melanoma, and to translate cutting-edge scientific research into clinical practice.[2][4] Sonegas looks to identify new biomarkers of disease, and the mechanisms of cellular stress that are deregulated in melanoma. Her group were the first to describe a lymphoreporter (MetAlert) mice for non-invasive imaging of pre-metastatic niches in melanoma. This allowed her to understand the mechanisms of immune resistance as well as to generate nanoparticle-based treatments.[citation needed]
Awards and honors
- Dana Ashby Young Investigator Award of the Society for Melanoma Research[3]
- 2009 Premio M. Josefa Wonenburger from the Xunta de Galicia[5]
- 2013 Melanoma Research Alliance Award[6]
- 2016 L’Oreal-MRA Women-Lead Team Award[7]
- 2022 Elected to the European Molecular Biology Organization[8]
- 2022 Pezcoller-Marina Larcher Fogazzaro-EACR Women in Cancer Research Award[3]
Selected publications
- Soengas MS; Capodieci P; Polsky D; et al. (1 January 2001). "Inactivation of the apoptosis effector Apaf-1 in malignant melanoma". Nature. 409 (6817): 207–211. doi:10.1038/35051606. ISSN 1476-4687. PMID 11196646. Wikidata Q31984891.
- Chrysiis Michaloglou; Liesbeth C W Vredeveld; Marisol Soengas; et al. (1 August 2005). "BRAFE600-associated senescence-like cell cycle arrest of human naevi". Nature. 436 (7051): 720–724. doi:10.1038/NATURE03890. ISSN 1476-4687. PMID 16079850. Wikidata Q29619550.
- María S Soengas; Scott W Lowe (1 May 2003). "Apoptosis and melanoma chemoresistance". Oncogene. 22 (20): 3138–3151. doi:10.1038/SJ.ONC.1206454. ISSN 0950-9232. PMID 12789290. Wikidata Q35146577.
- Marisol Soengas; Alarcón RM; Yoshida H; Giaccia AJ; Hakem R; Mak TW; Lowe SW (1 April 1999). "Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition". Science. 284 (5411): 156–159. doi:10.1126/SCIENCE.284.5411.156. ISSN 0036-8075. PMID 10102818. Wikidata Q53425055.
References
- ^ www.axel-k.com. "María S. Soengas". CNIO. Retrieved 2022-07-09.
- ^ a b "Conference: ""Three-in-One" antimelanoma agents validated in vivo: differential targeting of tumor cells, the surrounding vasculature and the immune system"-Dra. Marisol Soengas, Head Melanoma Group, Dean for Academic Affairs, CNIO". CiMUS - USC - Universidad de Santiago de Compostela (in Spanish). 2015-03-24. Retrieved 2022-07-09.
- ^ a b c d "The Pezcoller-Marina Larcher Fogazzaro-EACR Women in Cancer Research Award | The European Association for Cancer Research". www.eacr.org. Retrieved 2022-07-09.
- ^ www.axel-k.com. "Melanoma Group". CNIO. Retrieved 2022-07-09.
- ^ "Premio María Josefa Wonenburger | Unidade Muller e Ciencia". unidadedamullereciencia.xunta.gal. Retrieved 2022-07-09.
- ^ "The Melanoma Research Alliance Foundation supports CNIO research". EurekAlert!. Retrieved 2022-07-09.
- ^ www.axel-k.com (2016-05-24). "An international team led by the CNIO receives a grant from L'Oréal Paris USA and the Melanoma Research Alliance to study metastatic melanoma". CNIO. Retrieved 2022-07-09.
- ^ "EMBO elects 67 new members and associate members – Press releases – EMBO". 2022-07-06. Retrieved 2022-07-09.
| Authority control databases: Academics |
|---|
 | This article needs additional or more specific categories. (July 2022) |